GE Healthcare Life Sciences Hosts Graduate Students from Japan - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GE Healthcare Life Sciences Hosts Graduate Students from Japan



GE Healthcare Life Sciences has formed a joint program with Osaka University to offer students access to GE Healthcare’s training and technologies for biopharmaceutical research and manufacturing, to help support future growth of the sector in Japan.  The program, Interdisciplinary Program for Biomedical Sciences (IPBS), is Osaka University’s government-funded commitment to graduate education, which aligns with GE Healthcare Japan’s “Life Sciences Academy,” a GE Healthcare initiative launched in April 2013 with the objective of supporting the development of life sciences researchers in Japan.  Of the 14 IPBS graduate students, four will visit GE Healthcare Life Science’s Uppsala site for three weeks.

While at GE Healthcare in Uppsala, the Osaka University students will experience life in an R&D laboratory, closely working with GE Healthcare scientists and engineers. The students will receive comprehensive training in GE Healthcare’s advanced bioprocessing technologies and gain experience of protein interaction analysis and laboratory-scale protein purification using GE Healthcare instruments including Biacore and MicroCal systems for label-free analyses and ÄKTA pure chromatography systems.

Source: GE Healthcare Life Sciences

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here